Press Releases

Media Inquiries - media@caredxinc.com

 
Press Releases
Date Title and Summary View
Feb 7, 2018 BRISBANE, Calif, Feb. 07, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financia...
Feb 5, 2018 BRISBANE, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announces they will have a significant presence at the Cutting Edge of Transplantation (...
Feb 1, 2018 BRISBANE, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces that the first patient was enrolled in the Kidney Allograft Outcomes Allo...
Jan 16, 2018 BRISBANE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announces that its President & Chief Executive Officer, Peter Maag, received the 2017 Tr...
Jan 8, 2018 BRISBANE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the fourth quarter and full year ended D...
Nov 20, 2017 BRISBANE, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces that CMS released the 2018 Clinical Laboratory Fee Schedule confirming th...
Nov 15, 2017 BRISBANE, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, today reported that it has agreed to immediately repay certain obligations related to C...
Nov 9, 2017 BRISBANE, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the third quarter ended September 30, 2017. Rec...
Nov 2, 2017 BRISBANE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, PhD., Chief Executive Officer, and Michael Bell, Chief F...
Oct 31, 2017 BRISBANE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that, as an inducement material to entering into employment with CareDx, ...
Page:
1
... NextLast
= add release to Briefcase